US EditionRoche’s US Subsidiary Genentech Breaks Ground on State-of-the-Art Manufacturing Facility in North Carolina, USA
The $700 million facility will create over 1,900 jobs and enhance production of next-generation metabolic medicines, supporting Roche's $50 billion US manufacturing expansion plan.
- On Monday, Genentech held a groundbreaking ceremony in Holly Springs, North Carolina, to begin construction of its first East Coast manufacturing facility, attended by U.S. Rep. Deborah Ross and Gov. Josh Stein.
- Genentech chose Holly Springs for its skilled biotech workforce, strong academic institutions and proximity to other life-science companies, building on recent investments like Amgen's $1 billion and Johnson & Johnson's $2 billion projects.
- The project involves a $700 million investment and a 700,000-square-foot facility that will create more than 1,900 jobs, with local incentives from the North Carolina Community College System, Department of Commerce’s Division of Workforce Solutions, Wake County, and Town of Holly Springs.
- The facility will be operational by 2029 and designed for high-volume, efficient production of metabolic medicines, including next-generation obesity treatments, boosting supply-chain resilience.
- The project joins other Roche U.S. initiatives including a gene therapy facility in Pennsylvania, a continuous glucose-monitoring unit, and an AI R&D facility in Massachusetts, aligning with industry pledges driven by pressure to onshore production.
13 Articles
13 Articles
Carolina Journal
Carolina Coast OnlineBiotech company Genentech breaks ground on Holly Springs facility
San Francisco-based Genentech, a member of the Roche Group, held a groundbreaking ceremony in Holly Springs Monday morning to mark the start of construction of its first East Coast manufacturing facility. The $700 million project is part of Genentech and Roche’s $50 billion investment in US manufacturing and infrastructure. The 700,000-square-foot facility, which will support the production of metabolic medicines, including next-generation tre…
Genentech breaks ground on $700 million manufacturing facility in the US
Genentech, a member of the Roche Group, has broken ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 65,000 sq m facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, […]
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
